Ranbaxy and Sun get FDA OK for generic Imitrex
This article was originally published in Scrip
Ranbaxy Laboratories' US subsidiary and Sun Pharma and its subsidiaries have received final approval from the US FDA to manufacture and market sumatriptan succinate tablets 25mg (base), and 50mg (base), generic versions of GlaxoSmithKline's antimigraine, Imitrex.
You may also be interested in...
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
The head of global vaccine and plasma segments, bioprocessing, at German multinational Merck discusses key aspects around evolving vaccine manufacturing to improve the efficiency and speed of response during a pandemic. Pre-existing manufacturing platforms, the executive says, could compress process development work and fast-track scale-up.
Glenmark and Sun Pharma introduce nintedanib generics in India at a fraction of the innovator product’s price, vying for a share of the IPF market where pirfenidone currently holds sway.